- Home
- JKS vs COLL Comparison
JKS vs COLL Comparison
Compare JKS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKS | COLL |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | JKS | COLL |
|---|---|---|
| Price | $9.91 | $22.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $24.80 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 852.2K | 828.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $9.99 | $21.65 |
| 52 Week High | $31.88 | $50.79 |
Technical Indicators
Market Signals| Indicator | JKS | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 27.42 | N/A |
| Support Level | $9.99 | N/A |
| Resistance Level | $17.28 | N/A |
| Average True Range (ATR) | 0.57 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 13.89 | 0.00 |
Price Performance
Historical ComparisonAbout JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), the Americas, Europe, Asia Pacific, and the Rest of the world.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.